Pharmazz Inc. Announces Two Presentations on Sovateltide as a Treatment for Acute Ischemic Stroke at the 14th World Stroke Congress

WILLOWBROOK, Ill., Oct. 26, 2022 (GLOBE NEWSWIRE) — Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced two presentations on sovateltide as a treatment for acute ischemic stroke at the 14th World Stroke Congress October 26-29, 2022, in Singapore.

Details for the presentations are as follows:

Title: A Randomized Multicenter Study to Determine The Efficacy of Sovateltide (Tycamzzi™) in Patients With Cerebral Ischemic Stroke
Presentation: Oral Presentation, #1714
Authors: A. Gulati (presenter), S. Adwani, V. Pamidimukkala, N. Agrawal, T. Ramakrishnan, H. Rai, D. Jain, N.Sundarachary, J. Pandian, V. Sardana, M. Sharma, G. Sidhu, S. Anand, D. Vibha, S. Aralikatte, D. Khurana, D. Joshi, U. Karadan, M. Imam
Session: 1200 – Free Communications 18: Clinical Trials I
Time/Date: 11:30 a.m. – 1 p.m. GMT+8, Saturday, October 29, 2022 (Singapore) / 11:30 p.m. – 1 a.m. EDT, Friday, October 28, 2022 (U.S.)
   
Title: Sovateltide (Tycamzzi™) Induces Neuronal Regeneration in The Adult Mammalian Cerebral Ischemic Brain By Stimulating Endothelin B Receptors
Presentation: E-Poster Presentation, #1763
Authors: A. Gulati (presenter), A. Ranjan, S. Briyal
Session: 0150 – Short Communications 02: Etiology and Clinical Presentations 02
Time/Date: 10 – 11:30 a.m. GMT+8, Wednesday, October 26, 2022 (Singapore) / 10 – 11:30 p.m. EDT, Tuesday, October 25, 2022 (U.S.)

About Pharmazz, Inc. 
Pharmazz, Inc. is a privately held company engaged in developing novel products in critical care medicine. Additional information may be found on the Company’s website, www.pharmazz.com.  

Media contacts:
Katie Larch / Robert Flamm, Ph.D.
Burns McClellan, Inc.
Email: klarch@burnsmc.com / rflamm@burnsmc.com

Investor contacts:
Eric Ando
Burns McClellan, Inc.
Email: eando@burnsmc.com

Shruti Gulati
Pharmazz Inc.
Email: shruti.gulati@pharmazz.com 
Phone: (630) 780-6087

 

Staff

Recent Posts

Restart Life Sciences Signs Binding LOI to Acquire The Holy Crap Foods Portfolio of Brands and Manufacturing Plant

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

40 minutes ago

Functional Brands Inc. Launches Kirkman’s(R) Skin, Beauty & Anti-Aging Bundle: A Science-Backed Approach to Radiant, Resilient Skin

Comprehensive Formula Featuring Reduced Glutathione, Zinc Cream, Biotin, and Grapefruit Seed ExtractLake Oswego, Oregon--(Newsfile Corp.…

40 minutes ago

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces…

2 hours ago

XRP Healthcare® Secures Global Trademark Protection at the Intersection of Healthcare Services and XRP-Powered Payments

Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…

3 hours ago

Black Book Poll: “Governed AI” Emerges as the Deciding Factor in 2026 NHS Procurement

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…

3 hours ago

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…

3 hours ago